Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego

At Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego in Warsaw, a major part of the research focuses on cardiovascular diseases, especially myocardial infarction, atrial fibrillation, heart failure, and inherited heart conditions. These studies aim to improve prevention, reduce complications, and evaluate new ways to protect heart function and lower the risk of serious events.

• Studies in acute myocardial infarction and atherosclerotic disease are testing better strategies to prevent future cardiovascular events.
• Research in heart failure, hypertrophic cardiomyopathy, and arrhythmogenic cardiomyopathy is exploring more effective symptom control and disease management.
• Trials in atrial fibrillation, hyperkalaemia, and myocardial injury after noncardiac surgery focus on safer treatment and complication prevention.

Overall, this clinical program combines treatment evaluation with efforts to improve long-term cardiovascular outcomes and patient safety.

The site has a strong portfolio in hematologic malignancies and oncology, including acute leukemia, lymphoma, multiple myeloma, and rare blood cancers. Research is centered on testing new therapies, improving remission rates, and supporting patients with relapsed or difficult-to-treat disease.

• Trials in acute lymphoblastic leukemia, acute myeloid leukemia, and myeloid leukemia in children with Down syndrome aim to improve cure rates and disease control.
• Studies in chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma are evaluating more effective targeted treatment options.
• Research in multiple myeloma, plasma cell dyscrasia, and CD19+ B cell neoplasms includes advanced immune-based approaches such as CAR T-cell therapy.

These studies reflect a broad effort to expand treatment choices for patients with both common and rare blood cancers.

Important research at this site addresses autoimmune diseases and chronic inflammation, including lupus, myasthenia gravis, multiple sclerosis, and related neurologic and kidney conditions. The trials are designed to better control disease activity, reduce relapses, and improve quality of life for patients with long-term immune disorders.

• Studies in subacute cutaneous lupus erythematosus, chronic cutaneous lupus erythematosus, and lupus nephritis are evaluating new ways to reduce skin and kidney inflammation.
• Research in generalized myasthenia gravis, MOG antibody-associated disease, and multiple sclerosis is focused on symptom control and relapse prevention.
• Trials in immune-mediated kidney disease and atypical hemolytic uremic syndrome aim to improve safety and effectiveness of treatment in complex inflammatory conditions.

This area shows a strong interest in therapies that target the immune system more precisely and support durable disease control.

The clinical trial program also covers kidney disease, metabolic disorders, and several rare diseases. Research includes conditions such as chronic kidney disease, IgA nephropathy, nephrotic syndrome, and inherited syndromes, with a focus on slowing progression and improving supportive care.

• Trials in chronic kidney disease, hypertension, and kidney transplant complications aim to improve long-term renal outcomes.
• Studies in type 1 diabetes and hyperkalaemia are exploring better disease management and safer treatment options.
• Rare disease research includes Marfan syndrome, spinal muscular atrophy, Duchenne muscular dystrophy, and hemophilia, with the goal of improving function and reducing complications.

These investigations highlight the site’s role in advancing care for both common chronic conditions and uncommon inherited disorders.

Another active area of research includes respiratory diseases, eye disease, and selected allergic and immune-mediated conditions. The trials are aimed at improving breathing outcomes, reducing inflammation, and testing new therapies for disorders that can significantly affect daily life.

• Research in idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease is evaluating approaches to slow lung function decline.
• Studies in thyroid eye disease and non-infectious uveitis are focused on reducing inflammation and preserving vision.
• Trials in allergic and immune-related conditions are exploring better symptom control and longer-term treatment benefit.

This portfolio shows interest in both chronic organ-specific disease and broader inflammatory conditions across several specialties.

The research environment at the Warsaw site also includes neurology and pediatric medicine, with studies that address both disease treatment and supportive care needs. These trials often focus on improving daily functioning, reducing disease burden, and making treatment more practical for children and young people.

• Studies in attention-deficit hyperactivity disorder and type 1 diabetes explore how to better manage coexisting conditions in children.
• Research in spinal muscular atrophy, myasthenic disorders, and neuromuscular disease aims to improve long-term function and treatment tolerance.
• Supportive care studies include work on nicotine dependence and treatment strategies that may help patients maintain healthier habits.

These trials add breadth to the site’s program by addressing both complex neurologic illness and practical care challenges across age groups.